Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase + mFOLFIRINOX in Advanced Pancreatic Cancer
NCT04292743Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of eryaspase in pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Georgetown University. Primary endpoint: Incidence of Grade 3 or 4 Adverse Events at 1 year. Started Dec 2020; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04292743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292743.